BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bordeaux Institute of Oncology - ECPv6.17.3.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.bricbordeaux.com/en/
X-WR-CALDESC:Events for Bordeaux Institute of Oncology
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250403T120000
DTEND;TZID=Europe/Paris:20250403T130000
DTSTAMP:20250401T100244Z
CREATED:20250331T154329Z
LAST-MODIFIED:20250401T100244Z
UID:49016-1743681600-1743685200@www.bricbordeaux.com
SUMMARY:Leica - Seminar and demonstration of the Confocal Stellaris microscope
DESCRIPTION:LEICA will be at BBS on April 2 and 3\, 2025\, to demonstrate the Confocal Stellaris microscope.\n\n\nClément Laigle\, LEICA Applications Engineer\, will present the various acquisition options at a unit seminar on Thursday April 3\, from 12 noon to 1 pm.\nTo register\, see email sent by Walid Mahfouf on 26/03. If you are not from BRIC\, contact walid.mahfouf@u-bordeaux.fr \nDemo sessions last from 1h to 1h30 and are open to 3 people. You can reserve your slots on the ENT reservation site in the “BBS4-Demo Stellaris” resource family. \n\nLeica contact:\nAndy Tempez\nProduct Specialist Confocal Microscopy\nFrance South\nandy.tempez@leica-microsystems.com\nMobile : +33 6 74 40 34 72
URL:https://www.bricbordeaux.com/en/event/leica-seminar-and-demonstration-of-the-confocal-stellaris-microscope/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/03/leica-seminaire-avril-2025-bric.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250403T140000
DTEND;TZID=Europe/Paris:20250404T120000
DTSTAMP:20250407T122608Z
CREATED:20250320T165759Z
LAST-MODIFIED:20250407T122608Z
UID:48992-1743688800-1743768000@www.bricbordeaux.com
SUMMARY:Innovation in oncology
DESCRIPTION:Your research could open up new perspectives!\nTechnology transfer is the key to innovation in oncology\, because it brings research advances to patients. How can we transform these scientific discoveries into concrete solutions for patients and society? How can we support you in this process?   \nTo answer these questions\, SATT Aquitaine\, Inserm-Transfert and the BRIC laboratory are organizing an information and exchange session on April 3 and 4\, 2025\, to explore the opportunities for commercialization and better understand the support mechanisms available. \nThis event is aimed at researchers\, engineers and doctoral students who want to find out more about how to get the most out of their work and the opportunities available to them. A unique opportunity to meet and exchange with technology transfer experts and explore new perspectives for your research.  \n \nInformation and contact: \nAndréa Le Brazidec : a.lebrazidec@ast-innovations.com \n\nMore details and registration at this link.\n———————–\nProgram\nThursday\, April 03 – 2pm-5pm: Understand and be inspired!\nLocation: Amphi Centre Broca Nouvelle – Aquitaine – RdC14h00 – Introduction with Frédéric Saltel\, Director of BRIC. \n14h10 – Feedback\nGrégoire Prevost\, entrepreneur in residence at the BRIC Lab\, will highlight the challenges and opportunities of technology transfer identified during his mission. \n\nWhat obstacles have been identified to technology transfer in the lab?\nWhy and how can you add value to your work?\nWhat are the opportunities for oncology research?\n\n15h00 – Innovation support schemes \nSATT Aquitaine and Inserm Transfert will be presenting their support services for researchers. \n\nHow can SATT Aquitaine and Inserm Transfert help you?\nWhat is the relationship between SATT Aquitaine and Inserm Transfert?\nWhat business model for technology transfer?\nA few examples of value-adding in the healthcare sector.\n\n15h50 – The concrete case of a BRIC start-up\nBy Madeleine Moscatelli CEO of BeLiver. \n16h10 – The OncoSTART consortium \nLucia Robert\, coordinator of OncoSTART and CEO of MATWIN\, will present this program dedicated to researchers wishing to enter the field of oncology. \n16h30 – Informal exchange over a snack \n\nFriday\, April 04 – 09h-12h: Taking action!\nLocation: Meeting room S.2040 Est (BBS – Salles R+2)\, on registration09h00 – Workshops: Structuring your oncology project\nTake advantage of Grégoire Prevost’s expertise to work on the positioning and value of your research results\, analyze its strengths\, weaknesses\, opportunities and threats\, and start building a structured action plan. \n\nEvaluate your project with a strategic SWOT analysis.\nDetermine your invention’s Target Product Profile\, used to describe the ideal characteristics of a product prior to development.\nDesign your roadmap to define the steps and milestones you need to reach to bring your project to fruition.
URL:https://www.bricbordeaux.com/en/event/innovation-in-oncology/
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/03/journee-de-formation-a-la-valorisation--pui-bordeaux-bric-avril-2025.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250415T140000
DTEND;TZID=Europe/Paris:20250415T170000
DTSTAMP:20250317T161408Z
CREATED:20250317T154528Z
LAST-MODIFIED:20250317T161408Z
UID:48931-1744725600-1744736400@www.bricbordeaux.com
SUMMARY:Thesis defense Marine JAUVAIN\, team 4
DESCRIPTION:Defense of thesis in Microbiology – Immunology \nMarine JAUVAIN\, University hospital assistant\nTeam 04 – Helicobacter-associated digestive cancers\, cancer stem cells and therapeutic strategies.\nThesis supervision Émilie BESSEDE \nTuesday\, April 15 – 2pm Amphi BBS (Bordeaux Biologie Santé) site Carreire Université de Bordeaux – 2 rue du Dr Hoffmann Martinot – Bordeaux \n“Étude du microenvironnement bactérien dans le contexte de la carcinogenèse gastrique.”
URL:https://www.bricbordeaux.com/en/event/thesis-defense-marine-jouvain-team-4/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars,Thesis defenses
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/03/soutenance-de-these-marine-jauvain-team-4.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250415T140000
DTEND;TZID=Europe/Paris:20250415T170000
DTSTAMP:20250331T133552Z
CREATED:20250317T161656Z
LAST-MODIFIED:20250331T133552Z
UID:48937-1744725600-1744736400@www.bricbordeaux.com
SUMMARY:Thesis defense Marine JAUVAIN\, team 4
DESCRIPTION:Defense of thesis in Microbiology – Immunology \nMarine JAUVAIN\, University hospital assistant\nTeam 04 – Helicobacter-associated digestive cancers\, cancer stem cells and therapeutic strategies.\nThesis supervision Émilie BESSEDE \nTuesday\, April 15 – 2pm Amphi BBS (Bordeaux Biologie Santé) site Carreire Université de Bordeaux – 2 rue du Dr Hoffmann Martinot – Bordeaux \n“Étude du microenvironnement bactérien dans le contexte de la carcinogenèse gastrique.” \nSummary and notice of defense available at this link
URL:https://www.bricbordeaux.com/en/event/thesis-defense-marine-jauvain-team-4/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars,Thesis defenses
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/03/soutenance-de-these-marine-jauvain-team-4.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250418T110000
DTEND;TZID=Europe/Paris:20250418T120000
DTSTAMP:20250415T075049Z
CREATED:20250414T093133Z
LAST-MODIFIED:20250415T075049Z
UID:49146-1744974000-1744977600@www.bricbordeaux.com
SUMMARY:Invited seminar Léa Lemaitre - 18-04-2025
DESCRIPTION:Dr Léa Lemaitre \nPost Doc\, Division of Gastroenterology and Hepatology\, Stanford University\, Stanford\, CA\, USA \ninvited by Christophe Grosset\, team 6 MIRCADE\, Methods and Innovations for the Research in Pediatric Cancers. \nTitle: Targeting Macrophage-Mediated Mechanisms of Immune Evasion as adjuvant therapy in TACE-resistant Hepatocellular Carcinoma. \n  \nAbstract: \nA key obstacle to progress in treatment of hepatocellular carcinoma (HCC) is the notorious tenacity of HCC to recur. Transarterial chemoembolization (TACE) is the most common treatment for unresectable HCC\, however\, it fails to provide a durable cure. The crux of the problem lies in residual cancer cells that persist after TACE. Our goal is to understand how these residual cells escape immune detection and survive after TACE in order to develop effective adjuvant therapies.    \nWe used both in vitro and in vivo methods to mimic TACE- resistance by generating doxorubicin resistant- residual HCC models. We performed single-cell RNA sequencing on 3D tumoroids (31\,000 cells) of doxorubicin resistant vs control HCC in coculture with macrophages. In addition\, HCC patient-derived tumor cells and macrophages were used for validation. We developed an immunocompetent mouse model of syngeneic orthotopic allograft model of HCC\, using doxorubicin-resistant or control HCC cell lines to test adjuvant therapies.    \nUsing scRNAseq of 3D tumoroid model\, we show that doxorubicin-resistant cancer cells exhibit a stem-cell-like phenotype with high expression of stemness markers (CK19\, CD44)\, TGFb pathway (TGFBR1) and cytokines driving pro- tumor macrophage polarization (CXCL8\, CCL2). On the other hand\, the macrophages co-cultured with doxorubicin-resistant HCC showed a pro-tumor phenotype with increased PDL1 expression. We validated this finding using patient-derived samples\, showing that doxorubicin resistant HCC tumoroid co- culture increased PDL1 expression on macrophages. Further\, mRNA FISH showed that the CD68+ macrophages expressed higher levels of TGFB1 in TACE-resistant HCC than primary HCC (p=0.0011). Based on our in vitro analysis we identified the TGFB pathway and PDL1 as potential synergistic targets for adjuvant therapy of TACE-resistant HCC. In our mouse model of doxorubicin-resistant orthotopic allografts\, we showed that treatment with combined TgfbrI and anti-Pdl1 antibodies resulted in significantly reduced liver tumor burden (p=0.01). Flow cytometry analysis revealed immune remodeling with increased infiltration of CD8T cells and M1-like macrophage (CD86+/MHC- II+)\, along with depletion of macrophages (PDL1+/CD206+) in the liver of treated doxorubicin-resistant orthotopic allografts.       \nWe generated in vitro 3D models of TACE-resistance in HCC and identified the mechanistic roles of the PDL1+ macrophage-derived TGFβ1 on stem-like cancer cell persistence. We developed a mouse model of doxorubicin-resistant HCC and demonstrated that combined targeting of Pdl1 and Tgfb1 blocks tumor progression and evokes and anti-tumor macrophage and CD8T cell immune response. Thus combined targeting of PDL1 and TGFB1 holds therapeutic potential as adjuvant therapy in TACE to eliminate residual HCC\, reduce recurrence and improve patient outcomes in HCC.   \n  \nBiosketch: \nMy long-term research goals are to improve immunotherapies for cancer treatment. My objective is to decipher the complexity of the immune system in the tumor microenvironment. My academic training as a pharmacist and research scientist provides me with a strong background in pharmacy\, medicine\, clinical research\, immunology\, and oncology.   \nIn my first year of pharmacy residency\, I was involved in clinical trials\, and I developed a novel chromatographic method to detect errors in the administration of intravenous chemotherapy. During my residency\, I developed a strong interest in oncology research leading me to pursue an integrated masters program under the mentorship of Dr. Bettina Couderc. I analyzed the crosstalk between macrophages and mesenchymal stromal cells (MSCs) in chemotherapy-resistant ovarian cancer leading to 3 co-author publications. This research project reinforced my passion for immune-oncology. To further understand the role of MSCs in cancer resistance to therapies\, I pursued PhD training under the supervision of Dr. Bettina Couderc and Jill Corre\, entitled “Phenotypic and functional characterization of cancer-associated MSCs in multiple myeloma”. This work advanced the understanding of the tumor microenvironment in multiple myeloma and led to the publication of two first-authored publications (1\, 2). During my doctoral and postdoctoral training\, I was also involved in another project to decipher mechanisms of resistance to immunotherapy\, the results were published in Immunity with me as the second author (3). I thus gained strong training and expertise in tumor immunology and novel immune monitoring technologies.          \nThree years ago\, I joined the Dhanasekaran Lab to deepen my expertise in immuno-oncology. I have gained proficiency in advanced technologies such as CyTOF\, spatial immunology and organoids. I have published a manuscript discussing macrophage-mediated mechanisms of resistance to immune checkpoint inhibitors (4\, co-author\, Cancer Res\, 2023) and an article identifying novel mechanisms of resistance to therapy in liver cancer (5\, first author\, Nat Cancer\, 2024). These papers serve as a cornerstone for my current application to develop a precision oncology platform for immunotherapy in HCC. Alongside my mentor\, I have crafted a comprehensive career development plan aimed at enhancing my abilities in grant writing\, mentoring\, teaching\, and communication.     \n  \n\nLea Lemaitre\, DoSouto Ferreira L\, Joubert MV\, Avet-Loiseau H\, Martinet L\, Corre J\, Couderc Imprinting of Mesenchymal Stromal Cell Transcriptome Persists even after Treatment in Patients with Multiple Myeloma. Int J Mol Sci. 2020 May 28.  \nLea Lemaitre\, Hamaidia M\, Descamps JG\, Do Souto Ferreira L\, Joubert MV\, Gadelorge M\, Avet-Loiseau H\, Justo A\, Reina N\, Deschaseaux F\, Martinet L\, Bourin P\, Corre J\, Espagnolle N. Toll-like receptor 4 selective inhibition in medullary microenvironment alters multiple myeloma cell growth. Blood advance. 2022 Jan 25; 6(2):672-678.  \nWeulersse M*\, Asrir A*\, Pichler AC*\, Lemaitre Lea\, Braun M\, Carrié N\, Joubert MV\, Le Moine M\, Do Souto L\, Gaud G\, Das I\, Brauns E\, Scarlata CM\, Morandi E\, Sundarrajan A\, Cuisinier M\, Buisson L\, Maheo S\, Kassem S\, Agesta A\, Pérès M\, Verhoeyen E\, Martinez A\, Mazieres J\, Dupré L\, Gossye T\, Pancaldi V\, Guillerey C\, Ayyoub M\, Dejean AS\, Saoudi A\, Goriely S\, Avet-Loiseau H\, Bald T\, Smyth MJ\, Martinet L.. ** co-authors. Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8 + T Cell Anti- tumor Functions and Limits the Efficacy of Cancer Immunotherapy. Immunity. 2020 Oct 13.\nRenumathy Dhanasekaran\, Aida Hansen\, Jangho Park\, Lea Lemaitre\, Nia Adeniji\, Sibu Kuruvilla\, Akanksha Suresh\, Josephine Zhang\, Varsha Swamy\, Dean W. Felsher. MYC overexpression drives immune evasion in hepatocellular carcinoma (HCC) that is reversible through restoration of pro- inflammatory macrophages. Cancer research. 2022 Dec 16.   \nLea Lemaitre*\, Nia Adeniji*\, Akanksha Suresh*\, Reshma Reguram\, Josephine Zhang\, Jangho Park\, Amit Reddy\, Alexandro E. Trevino\, Aaron T. Mayer\, Anja Deutzmann\, Aida Hansen\, Ling Tong\, Vinodhini Arjunan\, Neeraja Kambham\, Brendan Visser\, Monica Dua\, Andrew Bonham\, Nishita Kothary\, H. Blaize D’Angio\, Ryan Preska\, Yanay Rosen\, James Zou\, Vivek Charu\, Dean W. Felsher and Renumathy Dhanasekaran. Spatial Analysis Reveals Targetable Macrophage-Mediated Mechanisms of Immune Evasion in Hepatocellular Carcinoma Minimal Residual Disease. Nature cancer. 2024 Sept 20
URL:https://www.bricbordeaux.com/en/event/invited-seminar-lea-lemaitre-18-04-2025/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/04/seminar-lea-lemaitre-2025-04-18.jpg
END:VEVENT
END:VCALENDAR